The effect of probiotic and synbiotic use on glycemic control in women with gestational diabetes: A systematic review and meta-analysis

source extracted confidence: high 2026-04-09
#pregnancy #humans #female #diabetes-gestational #glycemic-control

The effect of probiotic and synbiotic use on glycemic control in women with gestational diabetes: A systematic review and meta-analysis

Çetinkaya et al., 2022 | Diabetes Res Clin Pract | Meta Analysis

Citation

Çetinkaya Özdemir Serap, Küçüktürkmen Paşa Büşra, ... Sert Havva. The effect of probiotic and synbiotic use on glycemic control in women with gestational diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2022-Dec;194:110162. doi:10.1016/j.diabres.2022.110162

Abstract

AIMS: To investigate the impact of probiotic/synbiotic use on glycemic control in women with gestational diabetes. METHODS: We searched the PubMed, Medline, Scopus, ScienceDirect, Web of Science, Cochrane Central Register of Controlled Trials, Dergipark, and Council of Higher Education Thesis Center databases through March 2022. Screening was performed according to the population, intervention, comparison, outcome and study type. This systematic review and meta-analysis were performed in accordance with the Preferred Reporting Items for Systematic Review and meta-analyses (PRISMA-2020) statement. RESULTS: Eight RCTs involving 551 patients were included in the meta-analysis. Probiotic use in women with gestational diabetes significantly decreased fasting blood glucose (mean difference: -1.43; 95 % CI: -2.78 to -0.09, p: 0.04) and serum insulin (mean difference: -3.66; 95 % CI: -5.04 to -2.27, p < 0.001). Moreover, the use of probiotics and synbiotics significantly reduced the HOMA-IR level compared to the control group (probiotic group: mean difference: -0.74; 95 % CI: -1.05 to -0.44, p < 0.001; synbiotic group: mean difference: -0.68; 95 % CI: -1.26 to -0.09, p: 0.02). CONCLUSIONS: The use of probiotics in women with GDM reduced fasting plasma glucose, fasting serum insulin, and HOMA-IR levels. In addition, the use of synbiotics decreased HOMA-IR. Probiotic/synbiotic use is promising as a potential therapy to assist in glycemic control in gestational diabetes. Further high-quality studies are required to determine their safety.

Key Findings

Eight RCTs involving 551 patients were included in the meta-analysis. Probiotic use in women with gestational diabetes significantly decreased fasting blood glucose (mean difference: -1.43; 95 % CI: -2.78 to -0.09, p: 0.04) and serum insulin (mean difference: -3.66; 95 % CI: -5.04 to -2.27, p < 0.001). Moreover, the use of probiotics and synbiotics significantly reduced the HOMA-IR level compared to the control group (probiotic group: mean difference: -0.74; 95 % CI: -1.05 to -0.44, p < 0.001; s

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 551
Age Range See abstract
Condition diabetes

MeSH Terms

  • Pregnancy
  • Humans
  • Female
  • Diabetes, Gestational
  • Glycemic Control
  • Blood Glucose
  • Synbiotics
  • Probiotics
  • Insulin
  • Dietary Supplements

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Meta-Analysis, Systematic Review, Journal Article
  • Vertical: probiotics

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09